CccDNA persistence during natural evolution of chronic VHB infection

Romanian Journal of Gastroenterology

Volumn 14, Issue 4, 2005, Pages 373-377

  Cǎruntu, Florin Alexandru ^a,c   Molagic, Violeta ^b  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Prof Dr Matei Bals Institute for Infectious Diseases   (Romania)

^c Clinica de Boli Infec ioase   (Romania)

Author keywords

CccDNA; Chronic viral B hepatitis; Hepatitis B virus; Natural history

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIRETROVIRUS AGENT; CIRCULAR DNA; COVALENTLY CLOSED CIRCULAR DNA; UNCLASSIFIED DRUG; VIRUS DNA;

CELL DEATH; CHRONIC DISEASE; CLINICAL TRIAL; DISEASE MARKER; DNA DETERMINATION; DNA REPLICATION; EVOLUTION; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LIVER CELL; MATHEMATICAL MODEL; NONHUMAN; PERSISTENT INFECTION; REVIEW; VIRUS VIRULENCE;

EID: 29744468790     PISSN: 12214167     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350:1118-1129.
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34:1225-1241.
3. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-68.
4. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular DNA in hepadnavirus infected cells. Cell 1986;47:451-460.
5. Zoulim F, Trepo C. Virus de l'hepatite B: replication et mecanismes d'action des antiviraux. Virologie 1997;3:197-215.
6. Zhu Y, Yamamoto T, Cullen J, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001;75:311-322.
7. Newbold JE, Xin H, Teneza M, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995;69:3350-3357.
8. Fourel I, Cullen JM, Saputelli J, et al. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J Virol 1994;68:8321-8330.
9. Guo JT, Zhou H, Liu C, et al. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J Virol 2000;74:1495-1505.
10. Thimme R, Wieland S, Steiger C, et al. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77:68-76.
11. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-829.
12. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondivising hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virys. J Virol 1997;71:9392-9399.
13. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005;42:302-308.
14. Summer J, Mason WS. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci USA 2004;101:638-640.
15. Miller RH, Robinson WS. Hepatitis B virus DNA in nuclear and citoplasmatic fractions of infected human liver. Virology 1984;137:390-399.
16. Werle-Lapostolle B, Bowden S, Locarnini S et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during Adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-1758.
17. Wong DK, Yuen MF, Yuan H, et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004;40:727-737.
18. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-624.
19. Zhang YY, Zhang BH, Theele D, Litwin S, Toll E, Summers J. Single cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus infected liver. Proc Natl Acad Sci USA 2003;100:12372-12377.
20. Rehermann B, Ferrari C, Pasquinelli C, Chisari F. The hepatitis B virus persists for decades after patients recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature Medicine 1996;2:1104-1108.
21. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the USA. NEJM 1999;341:1256-1263.
22. Dandri M, Burda MR, Will H, Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of closed circular DNA. Hepatology 2000;32:139-146.
23. Wu TT, Coates L, Aldrich CE, Summers J, Mason WS. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA syntesis is amplified by an intracellular pathway. Virology 1990;175:255-261.
24. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863-1869.
25. Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B:new perspectives for immune therapy. Hepatology 2001;33:963-971.
26. Tsiang M, Gibbs C. Analysis of HBV dynamics and its impact on antiviral development. In: Lau JYN, Hamatake R. eds. Hepatitis B and D protocols. Vol.11: Immunology, model systems and clinical studies. Totowa, NJ: Humana Press, 2004:361-377.